Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients with Septic Shock and Elevated Endotoxin Level

The EUPHRATES Randomized Clinical Trial

R. Phillip Dellinger, Sean M. Bagshaw, Massimo Antonelli, Debra M. Foster, David J. Klein, John C. Marshall, Paul M. Palevsky, Lawrence S. Weisberg, Christa A. Schorr, Stephen Trzeciak, Paul M. Walker

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Importance: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes. Objective: To test whether adding polymyxin B hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity. Design, Setting, and Participants: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017. Interventions: Two polymyxin B hemoperfusion treatments (90-120 minutes) plus standard therapy completed within 24 hours of enrollment (n = 224 patients) or sham hemoperfusion plus standard therapy (n = 226 patients). Main Outcomes and Measures: The primary outcome was mortality at 28 days among all patients randomized (all participants) and among patients randomized with a multiple organ dysfunction score (MODS) of more than 9. Results: Among 450 eligible enrolled patients (mean age, 59.8 years; 177 [39.3%] women; mean APACHE II score 29.4 [range, 0-71 with higher scores indicating greater severity), 449 (99.8%) completed the study. Polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days among all participants (treatment group, 84 of 223 [37.7%] vs sham group 78 of 226 [34.5%]; risk difference [RD], 3.2%; 95% CI, -5.7% to 12.0%; relative risk [RR], 1.09; 95% CI, 0.85-1.39; P =.49) or in the population with a MODS of more than 9 (treatment group, 65 of 146 [44.5%] vs sham, 65 of 148 [43.9%]; RD, 0.6%; 95% CI, -10.8% to 11.9%; RR, 1.01; 95% CI, 0.78-1.31; P =.92). Overall, 264 serious adverse events were reported (65.1% treatment group vs 57.3% sham group). The most frequent serious adverse events were worsening of sepsis (10.8% treatment group vs 9.1% sham group) and worsening of septic shock (6.6% treatment group vs 7.7% sham group). Conclusions and Relevance: Among patients with septic shock and high endotoxin activity, polymyxin B hemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days. Trial Registration: ClinicalTrials.gov Identifier: NCT01046669.

Original languageEnglish
Pages (from-to)1455-1463
Number of pages9
JournalJAMA - Journal of the American Medical Association
Volume320
Issue number14
DOIs
Publication statusPublished - Oct 9 2018

Fingerprint

Hemoperfusion
Polymyxin B
Septic Shock
Endotoxins
Randomized Controlled Trials
Mortality
Therapeutics
Organ Dysfunction Scores
Sepsis
APACHE
North America
Tertiary Care Centers
Critical Illness

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients with Septic Shock and Elevated Endotoxin Level : The EUPHRATES Randomized Clinical Trial. / Dellinger, R. Phillip; Bagshaw, Sean M.; Antonelli, Massimo; Foster, Debra M.; Klein, David J.; Marshall, John C.; Palevsky, Paul M.; Weisberg, Lawrence S.; Schorr, Christa A.; Trzeciak, Stephen; Walker, Paul M.

In: JAMA - Journal of the American Medical Association, Vol. 320, No. 14, 09.10.2018, p. 1455-1463.

Research output: Contribution to journalArticle

Dellinger, R. Phillip ; Bagshaw, Sean M. ; Antonelli, Massimo ; Foster, Debra M. ; Klein, David J. ; Marshall, John C. ; Palevsky, Paul M. ; Weisberg, Lawrence S. ; Schorr, Christa A. ; Trzeciak, Stephen ; Walker, Paul M. / Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients with Septic Shock and Elevated Endotoxin Level : The EUPHRATES Randomized Clinical Trial. In: JAMA - Journal of the American Medical Association. 2018 ; Vol. 320, No. 14. pp. 1455-1463.
@article{4e9bb5a4d4d04b898f3bba51439627fb,
title = "Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients with Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial",
abstract = "Importance: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes. Objective: To test whether adding polymyxin B hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity. Design, Setting, and Participants: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017. Interventions: Two polymyxin B hemoperfusion treatments (90-120 minutes) plus standard therapy completed within 24 hours of enrollment (n = 224 patients) or sham hemoperfusion plus standard therapy (n = 226 patients). Main Outcomes and Measures: The primary outcome was mortality at 28 days among all patients randomized (all participants) and among patients randomized with a multiple organ dysfunction score (MODS) of more than 9. Results: Among 450 eligible enrolled patients (mean age, 59.8 years; 177 [39.3{\%}] women; mean APACHE II score 29.4 [range, 0-71 with higher scores indicating greater severity), 449 (99.8{\%}) completed the study. Polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days among all participants (treatment group, 84 of 223 [37.7{\%}] vs sham group 78 of 226 [34.5{\%}]; risk difference [RD], 3.2{\%}; 95{\%} CI, -5.7{\%} to 12.0{\%}; relative risk [RR], 1.09; 95{\%} CI, 0.85-1.39; P =.49) or in the population with a MODS of more than 9 (treatment group, 65 of 146 [44.5{\%}] vs sham, 65 of 148 [43.9{\%}]; RD, 0.6{\%}; 95{\%} CI, -10.8{\%} to 11.9{\%}; RR, 1.01; 95{\%} CI, 0.78-1.31; P =.92). Overall, 264 serious adverse events were reported (65.1{\%} treatment group vs 57.3{\%} sham group). The most frequent serious adverse events were worsening of sepsis (10.8{\%} treatment group vs 9.1{\%} sham group) and worsening of septic shock (6.6{\%} treatment group vs 7.7{\%} sham group). Conclusions and Relevance: Among patients with septic shock and high endotoxin activity, polymyxin B hemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days. Trial Registration: ClinicalTrials.gov Identifier: NCT01046669.",
author = "Dellinger, {R. Phillip} and Bagshaw, {Sean M.} and Massimo Antonelli and Foster, {Debra M.} and Klein, {David J.} and Marshall, {John C.} and Palevsky, {Paul M.} and Weisberg, {Lawrence S.} and Schorr, {Christa A.} and Stephen Trzeciak and Walker, {Paul M.}",
year = "2018",
month = "10",
day = "9",
doi = "10.1001/jama.2018.14618",
language = "English",
volume = "320",
pages = "1455--1463",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "14",

}

TY - JOUR

T1 - Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients with Septic Shock and Elevated Endotoxin Level

T2 - The EUPHRATES Randomized Clinical Trial

AU - Dellinger, R. Phillip

AU - Bagshaw, Sean M.

AU - Antonelli, Massimo

AU - Foster, Debra M.

AU - Klein, David J.

AU - Marshall, John C.

AU - Palevsky, Paul M.

AU - Weisberg, Lawrence S.

AU - Schorr, Christa A.

AU - Trzeciak, Stephen

AU - Walker, Paul M.

PY - 2018/10/9

Y1 - 2018/10/9

N2 - Importance: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes. Objective: To test whether adding polymyxin B hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity. Design, Setting, and Participants: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017. Interventions: Two polymyxin B hemoperfusion treatments (90-120 minutes) plus standard therapy completed within 24 hours of enrollment (n = 224 patients) or sham hemoperfusion plus standard therapy (n = 226 patients). Main Outcomes and Measures: The primary outcome was mortality at 28 days among all patients randomized (all participants) and among patients randomized with a multiple organ dysfunction score (MODS) of more than 9. Results: Among 450 eligible enrolled patients (mean age, 59.8 years; 177 [39.3%] women; mean APACHE II score 29.4 [range, 0-71 with higher scores indicating greater severity), 449 (99.8%) completed the study. Polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days among all participants (treatment group, 84 of 223 [37.7%] vs sham group 78 of 226 [34.5%]; risk difference [RD], 3.2%; 95% CI, -5.7% to 12.0%; relative risk [RR], 1.09; 95% CI, 0.85-1.39; P =.49) or in the population with a MODS of more than 9 (treatment group, 65 of 146 [44.5%] vs sham, 65 of 148 [43.9%]; RD, 0.6%; 95% CI, -10.8% to 11.9%; RR, 1.01; 95% CI, 0.78-1.31; P =.92). Overall, 264 serious adverse events were reported (65.1% treatment group vs 57.3% sham group). The most frequent serious adverse events were worsening of sepsis (10.8% treatment group vs 9.1% sham group) and worsening of septic shock (6.6% treatment group vs 7.7% sham group). Conclusions and Relevance: Among patients with septic shock and high endotoxin activity, polymyxin B hemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days. Trial Registration: ClinicalTrials.gov Identifier: NCT01046669.

AB - Importance: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes. Objective: To test whether adding polymyxin B hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity. Design, Setting, and Participants: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017. Interventions: Two polymyxin B hemoperfusion treatments (90-120 minutes) plus standard therapy completed within 24 hours of enrollment (n = 224 patients) or sham hemoperfusion plus standard therapy (n = 226 patients). Main Outcomes and Measures: The primary outcome was mortality at 28 days among all patients randomized (all participants) and among patients randomized with a multiple organ dysfunction score (MODS) of more than 9. Results: Among 450 eligible enrolled patients (mean age, 59.8 years; 177 [39.3%] women; mean APACHE II score 29.4 [range, 0-71 with higher scores indicating greater severity), 449 (99.8%) completed the study. Polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days among all participants (treatment group, 84 of 223 [37.7%] vs sham group 78 of 226 [34.5%]; risk difference [RD], 3.2%; 95% CI, -5.7% to 12.0%; relative risk [RR], 1.09; 95% CI, 0.85-1.39; P =.49) or in the population with a MODS of more than 9 (treatment group, 65 of 146 [44.5%] vs sham, 65 of 148 [43.9%]; RD, 0.6%; 95% CI, -10.8% to 11.9%; RR, 1.01; 95% CI, 0.78-1.31; P =.92). Overall, 264 serious adverse events were reported (65.1% treatment group vs 57.3% sham group). The most frequent serious adverse events were worsening of sepsis (10.8% treatment group vs 9.1% sham group) and worsening of septic shock (6.6% treatment group vs 7.7% sham group). Conclusions and Relevance: Among patients with septic shock and high endotoxin activity, polymyxin B hemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days. Trial Registration: ClinicalTrials.gov Identifier: NCT01046669.

UR - http://www.scopus.com/inward/record.url?scp=85054532732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054532732&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.14618

DO - 10.1001/jama.2018.14618

M3 - Article

VL - 320

SP - 1455

EP - 1463

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 14

ER -